Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia
Received 20 March 2007; received in revised form 4 July 2007; accepted 27 September 2007. published online 02 November 2007.
Abstract
Background
Mixed hyperlipidemia is a common disorder characterized by elevated VLDL and LDL levels. Patients with this syndrome usually are in need of combination therapy, comprising a fibric acid derivate with a statin drug in order to achieve LDL and triglyceride target values. Atorvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor demonstrated to be effective in reducing both cholesterol (CHOL) and triglyceride (TG) levels in humans. We examined the efficacy of atorvastatin as monotherapy in achieving a better or the same lipid profile in patients with mixed hyperlipidemia treated with combination therapy.
Design
We compared atorvastatin with a combination of a fibric acid derivate and a statin drug (other than atorvastatin) in a 24-week, prospective randomized, open-label study of 27 patients with mixed hyperlipidemia.
Methods
All 27 patients had been treated with statin–fibrate therapy in different regimens for at least a year. Atorvastatin at a daily dose of 20 mg was substituted for statin–fibrate therapy. Lipid and safety profiles were assessed.
Results
Atorvastatin significantly reduced total cholesterol, LDL-C, and HDL-C compared to statin–fibrate therapy. In contrast, TG and glucose levels were significantly elevated with atorvastatin. Target LDL-C and TG was achieved in 10 patients with the single therapy of atorvastatin vs. 6 patients under statin–fibrate. In 16 patients, atorvastatin was at least as effective as, or better than, the combination therapy, and was recommended for continuation of treatment.
Conclusion
Atorvastatin is an adequate monotherapy for many mixed hyperlipidemia patients. We recommend atorvastatin be considered for every patient suffering from mixed hyperlipidemia.
Bnai Zion Medical Center, Rambam Medical Center and the Technion Faculty of Medicine, Haifa, Israel
Corresponding author. Department Medicine C, Bnai Zion Medical Center, 47 Golumb St. Haifa, 31500, Israel. Tel.: +972 4 835 9131; fax: +972 4 835 9115.
ABSTRACT